Modality
Vaccine
MOA
BCL-2i
Target
GIP-R
Pathway
Proteasome
CKDObesityFSGS
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ May 2027
Phase 1Current
NCT04557181
731 pts·FSGS
2021-07→2025-07·Recruiting
NCT03420093
2,246 pts·FSGS
2025-07→2027-05·Terminated
2,977 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-149mo agoPh2 Data· FSGS
2027-05-051.1y awayPh2 Data· FSGS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Recruit…
P1/2
Termina…
Catalysts
Ph2 Data
2025-07-14 · 9mo ago
FSGS
Ph2 Data
2027-05-05 · 1.1y away
FSGS
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04557181 | Phase 1/2 | FSGS | Recruiting | 731 | ORR |
| NCT03420093 | Phase 1/2 | FSGS | Terminated | 2246 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |